Table 2.
Mean outcomes differences before matching.
| All cohort outcomes | Total (n = 544) | Tocilizumab (n = 197) | Control (n = 347) | p Value |
|---|---|---|---|---|
| In hospital mortality | 101 (18.6) | 50 (25.4) | 51 (14.7) | 0.002 |
| Overall mortality | 105 (19.3) | 51 (25.9) | 54 (15.6) | 0.003 |
| Overall stay (days) | 12.3 ± 9.5 | 14.7 ± 9.4 | 11.1 ± 9.4 | 0.008 |
| In hospital stay (days) | 11.1 ± 6.4 | 13.2 ± 5.8 | 10.0 ± 6.6 | 0.001 |
| ICU stay (days) | 8.4 ± 6.3 | 5.8 ± 4.3 | 11.8 ± 7.0 | <0.001 |
| Mortality (ICU patients) | 20 (22.0) | 9 (17.3) | 11 (28.2) | 0.214 |
| Early administration outcomes | Total (n = 494) | Tocilizumab (n = 147) | Control (n = 347) | p Value |
|---|---|---|---|---|
| In hospital mortality | 83 (16.8) | 32 (21.8) | 51 (14.7) | 0.056 |
| Overall mortality | 87 (17.6) | 33 (22.5) | 54 (15.6) | 0.067 |
| Overall stay (days) | 11.7 ± 9.0 | 13.5 ± 12.0 | 11.0 ± 9.3 | 0.012 |
| In hospital stay (days) | 10.6 ± 6.2 | 12.2 ± 4.8 | 10.0 ± 6.6 | 0.002 |
| ICU stay (days) | 8.7 ± 6.6 | 5.7 ± 4.5 | 11.8 ± 7.0 | <0.001 |
| Mortality (ICU patients) | 18 (22.5) | 7 (17.1) | 11 (28.2) | 0.226 |
Data are presented as n (%) unless continuous variables (days) presented as mean ± SD.